Published in JAMA on February 02, 2006
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev (2007) 6.38
Structural basis for the function and inhibition of an influenza virus proton channel. Nature (2008) 5.69
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04
Antiviral resistance and the control of pandemic influenza. PLoS Med (2007) 3.92
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog (2008) 2.49
Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A (2009) 2.44
Unifying vertical and nonvertical evolution: a stochastic ARG-based framework. Syst Biol (2009) 2.40
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother (2008) 2.39
Cellular networks involved in the influenza virus life cycle. Cell Host Microbe (2010) 2.23
The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol (2008) 2.19
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog (2008) 2.09
Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis (2010) 2.03
Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res (2008) 1.86
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog (2010) 1.81
Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. Biochemistry (2010) 1.73
Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis (2009) 1.64
Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol (2008) 1.62
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One (2010) 1.59
Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol (2006) 1.54
Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol (2008) 1.51
The genomic rate of molecular adaptation of the human influenza A virus. Mol Biol Evol (2011) 1.48
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A (2009) 1.48
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry (2009) 1.47
The feasibility of using high resolution genome sequencing of influenza A viruses to detect mixed infections and quasispecies. PLoS One (2009) 1.46
The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol J (2008) 1.45
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A (2011) 1.42
Influenza. Crit Care Med (2008) 1.39
The interplay of functional tuning, drug resistance, and thermodynamic stability in the evolution of the M2 proton channel from the influenza A virus. Structure (2008) 1.38
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses (2013) 1.37
Structural basis for proton conduction and inhibition by the influenza M2 protein. Protein Sci (2012) 1.36
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother (2010) 1.36
Magic angle spinning NMR investigation of influenza A M2(18-60): support for an allosteric mechanism of inhibition. J Am Chem Soc (2010) 1.36
Seasonal and pandemic influenza surveillance considerations for constructing multicomponent systems. Influenza Other Respir Viruses (2009) 1.35
Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel. Biochem Biophys Res Commun (2010) 1.35
Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res (2008) 1.30
Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc (2009) 1.28
Adamantane resistance in influenza A. JAMA (2006) 1.25
Changes in prescribing of antiviral medications for influenza associated with new treatment guidelines. Am J Public Health (2009) 1.25
Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. Clin Microbiol Rev (2012) 1.23
RNA virus genomics: a world of possibilities. J Clin Invest (2009) 1.23
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob Agents Chemother (2009) 1.23
The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology (2009) 1.21
Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother (2009) 1.20
Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host Microbe (2014) 1.19
In vitro inhibition of human influenza A virus replication by chloroquine. Virol J (2006) 1.18
Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure (2011) 1.18
Evolution in health and medicine Sackler colloquium: The comparative genomics of viral emergence. Proc Natl Acad Sci U S A (2009) 1.16
Magic-angle-spinning NMR of the drug resistant S31N M2 proton transporter from influenza A. J Am Chem Soc (2012) 1.16
Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza Other Respir Viruses (2009) 1.16
High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen (2008) 1.15
Influenza viruses: breaking all the rules. MBio (2013) 1.14
Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. J Virol (2013) 1.13
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol (2014) 1.13
A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One (2007) 1.12
The effect of population structure on the emergence of drug resistance during influenza pandemics. J R Soc Interface (2007) 1.12
A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine (2011) 1.12
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res (2013) 1.11
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog (2010) 1.11
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J (2011) 1.10
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother (2010) 1.09
Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol (2010) 1.08
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med (2008) 1.08
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res (2010) 1.07
Deep sequencing: becoming a critical tool in clinical virology. J Clin Virol (2014) 1.07
Recent progress in structure-based anti-influenza drug design. Drug Discov Today (2012) 1.06
Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. Biophys J (2009) 1.05
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem (2013) 1.03
Universal detection and identification of avian influenza virus by use of resequencing microarrays. J Clin Microbiol (2009) 1.02
Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding. Biophys J (2012) 1.02
Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol (2012) 1.02
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol (2011) 1.02
Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol (2015) 1.02
A pH-dependent conformational ensemble mediates proton transport through the influenza A/M2 protein. Biochemistry (2010) 1.01
Flu channel drug resistance: a tale of two sites. Protein Cell (2010) 1.01
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J Med Chem (2011) 1.00
Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother (2013) 1.00
Rapid detection and subtyping of human influenza A viruses and reassortants by pyrosequencing. PLoS One (2011) 1.00
Antiviral prescriptions to U.S. ambulatory care visits with a diagnosis of influenza before and after high level of adamantane resistance 2005-06 season. PLoS One (2010) 0.99
Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respir Viruses (2009) 0.99
Genetic analysis of influenza A/H3N2 and A/H1N1 viruses circulating in Vietnam from 2001 to 2006. J Clin Microbiol (2007) 0.99
Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS One (2010) 0.97
Computational study of drug binding to the membrane-bound tetrameric M2 peptide bundle from influenza A virus. Biochim Biophys Acta (2010) 0.96
A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog (2012) 0.96
In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob Agents Chemother (2010) 0.96
Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. J Clin Microbiol (2009) 0.95
Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One (2015) 0.94
Where does amantadine bind to the influenza virus M2 proton channel? Trends Biochem Sci (2010) 0.94
Stochastic model of an influenza epidemic with drug resistance. J Theor Biol (2007) 0.93
Assay to detect H5N1 oseltamivir resistance. Emerg Infect Dis (2006) 0.93
Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR. J Am Chem Soc (2013) 0.92
Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol J (2009) 0.92
Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. J Clin Microbiol (2010) 0.92
A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One (2012) 0.91
Baicalein, Ethyl Acetate, and Chloroform Extracts of Scutellaria baicalensis Inhibit the Neuraminidase Activity of Pandemic 2009 H1N1 and Seasonal Influenza A Viruses. Evid Based Complement Alternat Med (2013) 0.90
Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol (2011) 0.90
Epidemiologic study of influenza infection in Okinawa, Japan, from 2001 to 2007: changing patterns of seasonality and prevalence of amantadine-resistant influenza A virus. J Clin Microbiol (2009) 0.90
Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza Other Respir Viruses (2009) 0.90
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med (2005) 14.59
H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet (2009) 12.32
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
The allelic architecture of human disease genes: common disease-common variant...or not? Hum Mol Genet (2002) 10.08
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med (2009) 9.06
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep (2008) 9.02
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis (2012) 8.02
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med (2005) 6.83
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Transmission of equine influenza virus to dogs. Science (2005) 6.11
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis (2002) 5.92
Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA (2005) 5.84
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med (2003) 5.60
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep (2007) 5.32
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 5.19
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2004) 5.00
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med (2007) 4.16
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med (2013) 3.88
Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A (2007) 3.77
Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis (2006) 3.66
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2005) 3.50
Influenza vaccine effectiveness in the community and the household. Clin Infect Dis (2013) 3.40
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis (2012) 3.35
Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol (2007) 3.33
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2002) 3.27
Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis (2009) 3.26
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology (2011) 3.19
Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. J Infect Dis (2010) 3.02
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis (2013) 3.00
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2003) 2.96
The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis (2004) 2.96
Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis (2012) 2.91
Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes (2007) 2.91
The burden of influenza-associated critical illness hospitalizations. Crit Care Med (2014) 2.84
Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses (2009) 2.82
Serologic evidence of H1 swine Influenza virus infection in swine farm residents and employees. Emerg Infect Dis (2002) 2.75
Household responses to school closure resulting from outbreak of influenza B, North Carolina. Emerg Infect Dis (2008) 2.74
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis (2009) 2.56
Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51
Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA (2010) 2.48
Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957-1972: evidence for genetic divergence and multiple reassortment events. Virology (2004) 2.44
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis (2013) 2.38
Human case of swine influenza A (H1N1) triple reassortant virus infection, Wisconsin. Emerg Infect Dis (2008) 2.38
Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog (2008) 2.38
Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol (2009) 2.33
Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis (2012) 2.30
Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics (2008) 2.29
A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. Cell (2013) 2.28
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
Influenza- and RSV-associated hospitalizations among adults. Vaccine (2006) 2.23
Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends. PLoS One (2011) 2.21
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother (2009) 2.09
Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics (2004) 2.08
Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis (2013) 2.07
Family clustering of avian influenza A (H5N1). Emerg Infect Dis (2005) 2.04